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Abstract
Background: The risk of premature cardiovascular disease in patients with familial hypercholesterolemia (FH) can be
profoundly reduced by cholesterol-lowering therapy, and current guidelines for FH advocate ambitious low-density
lipoprotein cholesterol (LDL-C) goals. In the present study, we determined whether these goals are reflected in current
clinical practice once FH has been diagnosed.
Methodology/Principal Findings: In 2008, we sent questionnaires to all subjects (aged 18–65 years) who were molecularly
diagnosed with FH in the year 2006 through the screening program in the Netherlands. Of these 1062 subjects, 781
completed the questionnaire (46% males; mean age: 42612 years; mean LDL-C at molecular diagnosis (baseline):
4.161.3 mmol/L). The number of persons that used cholesterol-lowering therapy increased from 397 (51%) at baseline to
636 (81%) after diagnosis. Mean treated LDL-C levels decreased significantly to 3.261.1 mmol/L two years after diagnosis.
Only 22% achieved the LDL-C target level of #2.5 mmol/L.
Conclusions/Significance: The proportion of patients using cholesterol-lowering medication was significantly increased
after FH diagnosis through genetic cascade screening. The attained LDL-C levels were lower than those reported in previous
surveys on medication use in FH, which could reflect the effect of more stringent lipid target levels. However, only a
minority of the medication users reached the LDL-C target.
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Introduction
Familial hypercholesterolemia (FH) is an inherited disorder of
lipid metabolism that predisposes to severe premature cardiovas-
cular disease (CVD).[1,2] Cholesterol-lowering therapy can
prevent or delay the onset of CVD and premature death in these
individuals.[3,4]
Although FH is relatively common (1:400 in The Netherlands),
many patients are not diagnosed at all or they are identified only
after symptomatic onset of CVD.[5] Therefore, a molecular
screening program was set up to actively identify all FH patients in
the Netherlands.[6] During the last five years, approximately 9000
FH mutation carriers were identified. However, the success of this
national screening program in preventing CVD depends also on
the acceptance of physicians and patients to start preventive
measures, including foremost cholesterol-lowering medication.
In 2001, we demonstrated that 38% of the participants used
cholesterol-lowering therapy before the screening compared to
86% two years after the molecular diagnosis.[7] In the years after
this survey, new evidence was presented on the benefit of statin
treatment. In fact, two large meta-analyses demonstrated a linear
relationship between LDL-C levels and the occurrence of coronary
heart disease in both primary and secondary prevention of
CVD.[8,9] Additionally, more aggressive treatment was shown to
further decrease CVD risk.[10,11] New treatment options as well
as the growing awareness among physicians of the beneficial effect
of aggressive LDL-C lowering have resulted in the development of
ambitious treatment targets for persons with FH.[12,13] Dutch
guidelines now recommend a LDL-C treatment target of
#2.5 mmol/L (97 mg/dL) for subjects with FH.[13] These new
insights and guidelines may have changed the treatment of FH
patients compared to the setting of the previous survey in 2001.[7]
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9220In the present study, we therefore assessed whether the
molecular screening program has improved the preventive care
for FH. In addition, we analyzed the determinants that predict the
decisions about cholesterol-lowering medication once a molecular
diagnosis of FH is made.
Methods
Ethics Statement
We recruited subjects from the database of the nation-wide
cascade screening program for FH in the Netherlands.[6] This
program was instituted by the Dutch government and approved
and financed by the Ministry of Health. All subjects who
consented to participate in the screening for the FH mutation
were also asked for written consent for additional scientific studies.
For our survey we only approached those who gave written
informed consent for additional studies. We received approval to
perform such a questionnaire follow-up study by the Medical
Ethical Committee of the Academic Medical Center of the
University of Amsterdam.
Patient Selection and Recruitment
Subjects between 18 and 65 years of age were potentially
eligible if they were visited in 2006 by a genetic fieldworker, a
functional FH mutation was identified, and the lipid profile was
assessed. We excluded patients if their address information was
incorrect or unavailable or if they had declared that they did not
want to be approached for scientific research. All probands with
whom family screening was initiated were excluded as well.
We sent a questionnaire by surface mail to all selected FH
patients in May 2008. Two months after the questionnaire had
been distributed, we sent a reminder to the subjects who had not
returned the questionnaire. If we had not received the question-
naire after six months, we contacted a random sample of the non-
responder population by telephone in order to elucidate the
medication use at follow-up, and inquired after their reasons for
non-response. We selected these non-responders per month in
which they were diagnosed, and we choose the months January,
April, July, and October in 2006. We subsequently phoned until
25 consecutively diagnosed individuals in each period had
consented to participate, which resulted in an additional number
of 100 participants.
Data on demographics, CVD risk factors, lipid profile and
medication use at baseline were extracted from the database of the
screening organization.
Outcome Measures
The primary endpoints were attained LDL-C levels and the
difference of the proportions treated persons at molecular
diagnosis (‘at baseline’) and on average two years after the
molecular diagnosis (‘at follow-up’). The secondary endpoints were
the differences in CVD risk factors and lipid profiles between the
individuals who were treated or had been treated with cholesterol-
lowering drugs and those who were never treated.
When untreated LDL-C levels or recent on-treatment levels
were not available, we imputed these LDL-C levels by means of
the estimated LDL-C lowering potency of a specific lipid-lowering
drug and dose. These potency scores were summarized in a
supplementary table (table S1). Potency scores for statins were
derived from Walma et al.[13] We estimated the potency of
ezetimibe as 1.20 based on the approximately 17% additional
LDL-C lowering when added to statins.[14] The potency of a resin
was estimated as 1.11 and that of fibrates and nicotinic acid
derivatives 1.05.[3] We calculated the age and sex specific
percentiles for the LDL-C levels for each subject based on
reference values of a Caucasian population.[15]
Statistical Analyses
Differences in continuous and binary variables between
subgroups were compared by linear or logistic regression analyses
with generalized estimating equations (GEE) in the SAS procedure
GENMOD accounting for correlations within families. The
association between initiation of treatment since molecular
diagnosis and demographics, clinical characteristics, and lipids,
was analyzed with logistic regression (GEE) for all individuals who
were treatment naı ¨ve at baseline. We assessed the relation between
treatment potency of the drug regimen used after the molecular
diagnosis and demographic, clinical, and lipid characteristics by
linear regression analyses (GEE) for all persons that had been
treated at baseline and/or during follow-up. We used paired t-tests
to compare LDL-C levels and potency of prescribed medication
within persons over time, e.g. at baseline and after on average two
years of follow-up. Variables with a skewed distribution were log-
transformed before analysis. A p-value,0.05 was considered
significant. Statistical analyses were performed with the SAS
package version 9.1 (SAS Institute Inc, Cary, NC, USA).
Results
Study Population
During 2006, a pathogenic LDLR or apolipoprotein B (ApoB)
mutation was identified in 341 probands with a clinical diagnosis of
FH. In the same period, a total of 4228 relatives aged between 18
and 65 years were screened for the presence of the specific mutation
that was identified in the proband. Such a mutation was identified
in 1328 of these relatives. Of these mutation carriers, 458 (34%)
were first, 257 (19%) were second, 276 (21%) were third and 312
(23%) were fourth or further degree relatives of the proband, and
for 25 (2%) we could not retrieve the distance from the proband.
We excluded 266 patients with FH: 134 had not given written
informed consent for additional studies at the time of molecular
diagnosis and of 132 we lacked up-to-date contact information. Of
the remaining 1062 persons, 781 (74%) completed the question-
naire of whom 100 completed it upon a telephone call. The two
main reasons for not returning the questionnaire by surface mail
were that they had not received the two mailings (n=33) or that
they had been too busy (n=30).
The 781 participants had a mean age (6 standard deviation
(SD)) of 42612 years and a mean LDL-C level at diagnosis of
4.161.3 mmol/L and 359 (46%) were male (table 1). The overall
prevalence of CVD was 10% (n=77). Most participants had a
LDL-receptor mutation (n=681; 87%). Of the 100 participants
with an ApoB mutation, 85 had the R3500Q mutation.[16]
The 281 non-participants, i.e. those who did not respond to the
questionnaires and could not be reached by telephone, were
significantly younger (36 vs. 42 years of age; p,0.001), had a lower
prevalence of CVD (4% vs. 10%; p=0.003), were more often
smokers (56% vs. 42%; p,0.001) and used less cholesterol-
lowering medication at baseline (37% vs. 51%; p,0.001) than the
781 participants.
Use of Cholesterol-Lowering Medication
At baseline, 397 of the 781 subjects (51%) already used
cholesterol-lowering medication and 239 of 384 initially untreated
persons (62%) started cholesterol-lowering treatment during
follow-up (figure 1). Hence, the total number of treated persons
increased from 397 (51%) at baseline to 636 (81%) during follow-
up (p,0.001). As expected, the group that initiated treatment
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compared to those starting during follow-up (97% vs. 81%,
respectively; p,0.001). During follow-up, a total of 55 patients
discontinued medication for various reasons: adverse events
(n=25; 45%); physician’s advice (n=14; 25%); intention to
become pregnant, pregnancy or to breastfeed (n=13; 24%); and
own choice (n=3; 5%).
Nearly one fifth (n=145) of the 781 participants never started
medication. The main reasons were physicians’ advice (n=82;
56%); own choice (n=56; 39%); intention to become pregnant,
pregnancy or to breastfeed (n=7; 5%).
LDL-C Levels at Molecular Diagnosis and Two Years after
Diagnosis
After two years of follow-up, the mean LDL-C level (6 SD
[interquartile range (IQR)]) of all participants, was significantly
reduced by 22% as compared with the level at baseline (3.261.1
[2.6–3.8] vs. 4.161.3 [3.2–4.9] mmol/L, respectively; p,0.001).
In the group of 239 treatment naı ¨ve persons that started
cholesterol-lowering medication after diagnosis the mean LDL-C
level (6 SD) was decreased with 44% from 5.161.3 at baseline to
2.860.80 mmol/L (p,0.001) two years later. The mean addi-
tional reduction in patients who were already treated at baseline
was 8%: from 3.560.9 to 3.260.9 mmol/L (p,0.001).
The mean baseline LDL-C levels 6 SD [IQR] differed
significantly between 239 treatment naı ¨ve subjects at diagnosis who
started medication during follow-up and 145 subjects who did not
initiate treatment (5.161.3 [4.2–5.7] vs. 3.961.3 [3.0–4.8] mmol/L,
respectively; p,0.001). The mean age and sex specific percentiles of
the untreated LDL-C levels were considerably higher in the subjects
that initiated medication after the molecular diagnosis than those
who did not (88th vs 68th percentile, respectively; p,0.001).
Characteristics of Treated and Untreated Individuals
The 636 persons, who already used medication at baseline or
started during follow-up (i.e. ‘treated’), were older (44612 vs.
35612 years; p,0.001) than those 145 persons, who had never
used medication (i.e. ‘untreated’) (see table 1). As expected, the
treated patients had a higher prevalence of cardiovascular risk
factors than untreated patients, such as history of CVD, diabetes
mellitus, hypertension and history of smoking.
The proportion of ApoB mutation carriers among treated
subjects did not differ significantly from the proportion among
untreated subjects at follow-up (12% vs. 17%, respectively;
p=0.10). The four most prevalent LDLR mutations that had
been reported to result in a severe LDL-C and CVD phenotype,
i.e. V408M (exon 9), 1359-1 (intron 9), 313+1/2 (intron 3) and
W23X (exon 2), were more prevalent in the treated than in the
untreated group (97/636=15% vs. 7/145=5%; p,0.001).[17]
The treated carriers were more often first degree relatives of the
proband as compared to the non-treated carriers (231/636=36%
vs. 40/145=28%, p,0.001).
Table 1. aracteristics of treated and untreated FH patients.
Treated n=636 Untreatedn=145 p-value
Demographic and clinical
Age years 44612 35612 ,0.001
Male gender - n (%) 297 (47) 62 (42) 0.27
History of CVD - n( % ) 76 (12) 1 (1) 0.002
Diabetes mellitus - n( % ) 20 (3) 0 (0) 0.02
Hypertension - n( % ) 75 (12) 2 (1) ,0.001
Body mass index kg/m
2 2564.4 2463.8 ,0.001
Current smoker (at diagnosis) - n( % ) 277 (44) 52 (35) 0.05
Mutation
LDLR or ApoB – n (LDLR)/n (ApoB) 560/76 121/24 0.10
Lipids mmol/L
Untreated LDL-C
# 6.162.1 3.961.3 ,0.001
Percentile untreated LDL-C
# 92613 68629 ,0.001
Cholesterol at baseline






- Triglycerides - median [IQR] 1.1 [0.76–1.7]
* 1.0 [0.64–1.4] 0.006
Reported TC at follow-up 5.261.1
a 5.361.3
b 0.45




Potency of medication at baseline
e 1.8460.34
e ––
Potency of medication at follow-up 1.9060.35 – –
Data are expressed as mean 6 standard deviation unless otherwise indicated. Variables are based on information at time of molecular FH diagnosis in 2006 (baseline)
unless otherwise indicated. Follow-up is at completion of the questionnaire in 2008.
ApoB=apolipoprotein B; CVD=cardiovascular disease; HDL-C=high-density lipoprotein cholesterol; IQR=interquartile range; LDL-C=low-density lipoprotein
cholesterol; LDLR=LDL-receptor; TC=total cholesterol.
#Estimated LDL-C with correction for treatment potency at diagnosis when applicable;
*Based on mean LDL-C of
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a specialist than untreated patients: 312 (54%) visited an internist
and/or a cardiologist, whereas 26 of the 145 untreated patients
(18%) had visited a specialist. In fact, 65 (45%) of the untreated
patients responded that they did not visit a doctor at all with
regard to FH treatment.
Predictors of Initiation of Treatment
Among the 384 untreated subjects at baseline, increased age,
body mass index (BMI), LDL-C and triglycerides levels and low
levels of high-density lipoprotein cholesterol (HDL-C) were
associated with the start of medication after molecular diagnosis
in univariate analyses. After stepwise multivariate regression
analysis, age, LDL-C, and HDL-C independently predicted the
start of medication (table 2).
Characteristics of Used Cholesterol-Lowering Treatment
The mean potency of the medication of the 636 treated patients
was 1.9060.35. For the 397 subjects that already used cholesterol-
lowering medication at baseline, the LDL-C lowering capacity was
increased after the identification of their mutation from 1.8460.34
to 1.9960.36 (p,0. 001). A total of 265 (34%) participants used
dairy products enriched with sterols and stanols, with a similar
proportion in those did or did not use cholesterol-lowering
medication (34% vs. 33%, respectively; p=0.92).
Predictors of Potency of Treatment
For the 636 persons that used cholesterol-lowering medication
during follow-up, a number of variables were significantly
associated in the univariate analyses with the potency of the drug
regimen after diagnosis: increased age and BMI, history of CVD,
presence of diabetes or hypertension, smoking status at diagnosis,
high pre-treatment LDL-C and triglycerides, and low HDL-C.
After stepwise multivariate regression analysis, untreated LDL-C
levels, age, history of CVD, and diabetes were independent
predictors of the potency of the drug regimen used after the
molecular diagnosis (table 3).
LDL-C Target Attainment
Of the 781 participants, 297 (38%) persons could report a LDL-
C level at the end of follow-up: the target level of #2.5 mmol/L
was achieved in 65 (22%) persons. Based on the mean potency of
the current medication (1.90), we expected that 25% of the 636
treated patients would attain the target LDL-C level. In total, 492
of the 636 (77%) subjects that used cholesterol-lowering medica-
tion after diagnosis did not achieve LDL-C levels #2.5 mmol/L.
Figure 1. Use of cholesterol-lowering medication between molecular diagnosis of FH and completion of questionnaire. Molecular
diagnosis of FH was made in 2006 and the questionnaire was send and completed in 2008. AE=adverse events related to CLM; FH=familial
hypercholesterolemia; CLM=cholesterol-lowering medication; pregnancy=no use of medication due to pregnancy, intention to become pregnant or
breastfeeding.
doi:10.1371/journal.pone.0009220.g001
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LDL-C levels. Of the 145 subjects that remained untreated, 15
(10%) already had LDL-C levels #2.5 mmol/L at screening.
Discussion
In the current study, we found that mean LDL-C levels of
individuals, who were untreated at baseline, decreased by 44%
with treatment in the two years after molecular diagnosis. This
means that cascade screening by molecular diagnosis not only
leads to identification of FH but also supports the decision to treat
these new FH patients. The decision whether or not to initiate
lipid-lowering treatment was found to be dependent on age, and
HDL-C and LDL-C levels. The proportion of individuals on
cholesterol-lowering medication increased from 51% to 81%
during follow-up. In contrast, one fifth of the identified FH
subjects never started cholesterol-lowering medication. In the
majority of these cases the general practitioner advised to refrain
from medication because their untreated LDL-C levels were not so
severely increased, i.e. on average at the 68
th percentile, compared
to the treated persons, whose levels were at the age and sex specific
92
nd percentile before initiation of cholesterol-lowering drugs.
The achieved LDL-C level in all participants two years after
molecular diagnosis was significantly lower than the achieved level
in a similar survey in 2001: 3.2 mmol/L in 2008 vs. 4.2 mmol/L
in 2001.[7] This is likely a consequence of the more stringent
LDL-C targets for the FH population. Thus, ambitious goals and
treatment possibilities for patients with FH indeed seem to be
reflected by current clinical practice.
Surveys with a similar topic have also been performed in
Norway and the United Kingdom. The survey in Norway focussed
on medication use after molecular FH diagnosis among first
degree relatives of probands.[18] The proportion of treated adult
subjects increased from 67.5% at the time of genetic testing to
86.0% after six months. The decrease in LDL-C was 13.9% for
the entire group with a mean achieved LDL-C level of
4.361.4 mmol/L at 6 months follow-up. By contrast, in our
survey, we found significant lower achieved LDL-C levels (mean
3.261.1 mmol/L). This difference may be explained by a lower
baseline LDL-C level in our cohort, a longer follow-up period to
up-titrate the treatment and a more potent treatment regimen
than in the Norwegian survey.
Audits on management of FH patients in outpatient clinics
specifically were recently performed in the United Kingdom
(UK) and the Netherlands. In the UK, Hadfield and colleagues
showed that the proportion of patients on cholesterol-lowering
medication ranged between of 88-94% with on-treatment
LDL-C levels between 3.0 and 3.7 mmol/L.[19] Similarly,
Pijlman and colleagues found mean achieved LDL-C levels of
3.261.1 mmol/L with 96% of the patients being on statin
treatment for those visiting outpatient clinics in the Netherlands
since 2006. [20] In our study, the percentage of subjects on lipid-
lowering medication who visited a specialist amounted 93%,
which is rather similar to the percentages found by Pijlman et al.
and Hadfield et al. and much higher than the average
percentage (81%) in our entire cohort. Taken together, one
Table 3. Association of CVD risk factors with the potency of cholesterol-lowering drug regimen in all treated FH patients (n=636).
Univariate Multivariate
B [95% CI] p-value B [95% CI] p-value
Age years 0.0058 [0.10; 0.15] ,0.001 0.0030 [0.0009; 0.0052] 0.0057
Male gender 0.016 [20.034; 0.066] 0.53 – –
History of CVD 0.22 [0.14; 0.31] ,0.001 0.098 [0.02; 1.2] 0.019
Diabetes 0.23 [0.06; 0.41] 0.008 0.16 [0.02; 0.30] 0.030
Hypertension 0.16 [0.08;0.25] ,0.001 – –
Body Mass Index kg/m
2 0.0091 [0.003; 0.015] 0.0031 – –
Smoker at diagnosis 0.070 [0.02;0.12] 0.0089 – –
Untreat. LDL-C mmol/L 0.071 [0.056; 0.086] ,0.001 0.066 [0.054; 0.078] ,0.001
HDL-C mmol/L 20.089 [20.17; 20.013] 0.022 – –
Triglycerides
# mmol/L 0.053 [0.001; 0.10] 0.046 – –
Untreat. LDL-C= LDL-C level at FH diagnosis, when applicable corrected for lipid- lowering therapy use to calculate a pre-treatment value. CVD=cardiovascular disease;
HDL-C=high-density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol.
#log-transformed before analyses.
doi:10.1371/journal.pone.0009220.t003
Table 2. Association of CVD risk factors with initiation of
cholesterol-lowering medication in FH patients that were
untreated at diagnosis (n=384).
Univariate Multivariate
OR [95% CI] p-value OR [95% CI] p-value
Age years 1.03 [1.01–1.05] 0.0060 1.02 [1.0009 – 1.05] 0.041
Male gender 1.30 [0.88–1.92] 0.18 – –
History of CVD 1.07 [0.09–13.4] 0.96 – –




1.07 [1.01–1.12] 0.017 – –
Smoker at
diagnosis
1.29 [0.90–1.83] 0.16 – –
LDL-C mmol/L 2.11 [1.65–2.71] ,0.001 2.03 [1.60–2.58] ,0.001




1.69 [1.19–2.40] 0.0033 – –
CVD=cardiovascular disease; HDL-C=high-density lipoprotein cholesterol;
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off when referred to a specialized clinic. On the other hand, the
FH population that remained at the general practitioner’s office
clearly had a different phenotype with less raised LDL-C and
fewer risk factors.
In general, management of FH patients is not successful when
measured against the new guideline targets. In fact, a sizable
subset of persons with FH does not get pharmacological treatment
at all and the treatment target of LDL-C levels #2.5 mmol/L is
achieved only in 22% of the treated patients.[13] This failure to
meet LDL-C targets may be partly due to the hesitation of some
physicians and patients to use most potent available drug
regimens. This notion is supported by the findings of Pijlman
and colleagues, who conducted a cross-sectional study in five large
outpatient lipid clinics in The Netherlands. The main reason why
treating physicians did not prescribe maximum therapy to FH
patients despite an LDL-C .2.5 mmol/L, was because they
accepted that higher LDL-C level.[20] Another reason for not
reaching target levels is that some patients may not have been able
to due to extremely high LDL-C levels. In our study we found
that, of all treated patients who were not on target (LDL-
C#2.5 mmol/L), 36% had LDL-C levels that were reduced by
more than 50%. Nonetheless, LDL-C levels could have been
further reduced, since only a minority (5%) of all participants was
treated with potent dual therapy with the highest dose of
atorvastatin or rosuvastatin in combination with ezetimibe. The
estimated percentage of subjects that would have achieved an
LDL-C level #2.5 mmol/L would be 61% based on that most
potent lipid-lowering strategy. Thus, even with the most potent
dual treatment regimens, in some cases the Dutch target level can
not be reached. More potent options are needed.
One fifth of individuals with a molecular diagnosis of FH did
not use cholesterol-lowering medication at all. Almost half of the
untreated patients had not consulted a physician, which is
unexpected, since genetic field workers encouraged all subjects
who were found to have dyslipidemia at screening to visit their
physician. Moreover, those with confirmed molecular diagnosis
were explicitly urged to seek for medical consultation. The other
half did not start treatment even though they had consulted a
physician, which is remarkable. However, the FH patients who
remained untreated had on average few cardiovascular risk factors
and above all, absence of severe dyslipidemia. Whether this group
of FH ‘patients’ should receive medication based on mutation
carriership or not, is of scientific and clinical importance, and
should be further elucidated.[21,22]
It is intriguing to observe that a relatively large group of
subjects had a molecular diagnosis of FH but lacked a severe
dyslipidemia phenotype. One of the explanations could be a
high prevalence in this group of mild mutations such as ApoB
mutations, which in general result in a less severe FH phenotype
than LDLR mutations.[23] Indeed, we observe a non-significant
trend towards a higher prevalence of ApoB among those without
severe dyslipidemia in our study population. Conversely, the
LDLR mutations reported to result in a severe FH phenotype,
are less common in this group.[17] We further speculate that
some sequence variants, which were used in the cascade
screening programme in 2006 and assumed to cause FH, may
not be pathogenic after all. This could have explained the lack
of dyslipidemia in some subjects identified with molecular FH in
2006. An ongoing project aims to correctly label such sequence
variants as non-pathogenic.[24] A final possible explanation is
that other genetic variants counterbalanced the effect of the FH
mutation, such as concurrent ApoB or loss-of-function PCSK9
mutations that usually result in hypobetalipoproteinemia.[25–27]
We aim to perform additional studies in the near future to find
out whether the proposed putative explanations hold true.
One drawback of our approach is the possible bias inflicted by
non-participation. Based on the characteristics of the 281 patients
who did not participate, i.e. lower proportion of cholesterol-
lowering medication use at baseline, younger age and lower
prevalence of CVD as compared to the 781 participants, one
could reason that the proportion of treated subjects at follow-up
will be an overestimation. However, LDL-C levels and the
proportion of subjects that used of cholesterol-lowering medication
at follow-up did not differ between the 681 participants that
returned the questionnaire by surface mail and the 100 subjects
that completed the questionnaire by telephone. Assuming that
these 100 participants by telephone contact are a random sample
of the source population of which the 281 non-participants are a
part, we expect the impact of potential selection bias to be modest.
In conclusion, the molecular diagnosis of FH leads to an
increased proportion of patients that start or intensify cholesterol-
lowering medication, and consequently, to a robust decrease in
LDL-C levels. The attained LDL-C levels are lower than those
reported in a previous survey which could reflect the effect of more
stringent lipid target levels. However, only a minority of the
patients was treated with a potent drug regimen to reach set
targets.
Supporting Information
Table S1 Potency scoring for several cholesterol-lowering drugs.
*Potency scores for statins were derived from Walma Ned Tijdschr
Geneeskd 2006;150:18–23, who based the scores themselves on
Law BMJ 2003;326:1423-7. #Correction factor for ezetimibe was
based on 17% additional decrease in LDL-C (100%/(100%-
17%)=1.20) when added to statins (Kastelein NEJM 2008; 358:
1431-43). Our study population used relative low doses of bile acid
sequestrants and these were estimated to have only a modest effect
on LDL-C levels. Even lower potency scores were applied for
fibrates and nicotinic acid, which influence primarily triglyceride
and HDL-cholesterol levels respectively and have a modest effect
on LDL-C levels (Huijgen Expert Rev Cardiovasc Ther
2008;6:567-81).
Found at: doi:10.1371/journal.pone.0009220.s001 (0.05 MB
DOC)
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